Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8744685 | 0.99 | CYP2C19 (0.31) | CYP2C19HIF1APPARA | |
| SCHEMBL8744695 | 0.96 | CYP2C19 (0.33) | CYP2C19HIF1APPARAALDH1A1GAA | |
| SCHEMBL10258637 | 0.86 | CES1 (0.35) | CYP2C19HIF1APPARAALDH1A1 | |
| SCHEMBL12092669 | 0.85 | ACACB (0.40) | CYP2C19HIF1APPARA | |
| SCHEMBL3279812 | 0.85 | CYP2C19 (0.42) | CYP2C19HIF1APPARAALDH1A1TSHR | |
| SCHEMBL12092653 | 0.85 | ACACB (0.36) | CYP2C19HIF1APPARA | |
| SCHEMBL12092639 | 0.84 | ACACB (0.43) | CYP2C19HIF1APPARA | |
| SCHEMBL3279710 | 0.84 | CYP2C19 (0.41) | CYP2C19HIF1A | |
| SCHEMBL8744684 | 0.83 | CYP2C19 (0.36) | CYP2C19HIF1A | |
| SCHEMBL10258992 | 0.82 | CES1 (0.36) | CYP2C19HIF1APPARAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975300-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140228439-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8642653-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120129930-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129930-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, CETP | CYP2C19 431/4885HIF1A 776/4885PPARA 26/4885 |
| US-20140228439-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, GPR119 | CYP2C19 485/4885HIF1A 927/4885PPARA 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.